CD274 and neoplasm: To-date this list of approved PD-L1-targeting agents includes atezolizumab (TecentriqTM), avelumab (BavencioTM), and durvalumab (ImfinziTM) across multiple tumor types and lines of therapy (reviewed in [15]).